Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific
Bear Case

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

• The company is facing a significant financial headwind from an August 2026 cybersecurity incident, which Wells Fargo estimates could impact third-quarter results by approximately $300 million in sales and $0.13 per share in earnings. This substantial hit to profitability and revenue could pressure the company's ability to meet its full-year 2026 guidance of $3.280 to $3.320 in EPS.
• Boston Scientific Co. recently faced a product recall for its Imager II Angiographic Catheters due to a tip detachment defect, as flagged by the FDA. This recall poses potential risks to patient safety and could lead to increased regulatory scrutiny, legal liabilities, and reputational damage, which may further erode investor confidence and impact future sales in the cardiovascular segment.
• The stock has experienced a severe decline, reaching a new 52-week low of $41.94 in October 2026, down significantly from its 52-week high of $105.65. This downward trend, coupled with a 50-day simple moving average of $46.95 and a 200-day simple moving average of $51.51, indicates that the stock is in a strong downtrend, which may continue as investors reassess the company's risk profile.
• Analyst sentiment has deteriorated sharply, with multiple firms lowering their price targets in recent months. For example, Citigroup cut its target from $50.00 to $48.00, Oppenheimer reduced its target from $85.00 to $65.00, and Royal Bank of Canada lowered its target from $85.00 to $70.00. This widespread reduction in price targets reflects growing concerns about the company's near-term earnings potential and operational challenges.
• Short interest in Boston Scientific Co. has increased significantly, with shares shorted rising to 46,504,769 as of September 15, 2026, representing a 3.22% short percentage of the float. This increase in short interest suggests that a substantial portion of the market is betting against the stock, which could create additional downward pressure on the share price and indicate a lack of confidence in the company's ability to recover from recent setbacks.